LPCN
Lipocine Inc.
$2.26
+2.73%
$18.6M
No data for this timeframe.
Vol
Market Cap$18.6M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders17 funds
Inst. Value$4.1M
Inst. Activity2 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$434.6K
Reddit Sentiment23° Bearish
SEC Reports9
Recent Activity
Jun 4, 2026
SEC
Lipocine filed an 8-K announcing a virtual KOL event on June 12, 2026, to discuss unmet needs in postpartum depression a
8-K — Impact 3/10
Jun 3, 2026
Insider
Ono Richard Dana was granted 1,764 shares
Director @ $2.19 ($3.9K)
Jun 3, 2026
Insider
Jene Jill M. was granted 1,764 shares
Director @ $2.19 ($3.9K)
Jun 3, 2026
Insider
Higuchi John W. was granted 1,764 shares
Director @ $2.19 ($3.9K)
May 26, 2026
SEC
Lipocine announced the presentation of Phase 3 clinical data for LPCN 1154 (oral brexanolone) for postpartum depression
8-K — Impact 4/10
May 19, 2026
SEC
Lipocine announced that its Phase 3 clinical data for LPCN 1154 (oral brexanolone for postpartum depression) has been ac
8-K — Impact 4/10
Inst.
DIMENSIONAL FUND ADVISORS LP — ADD
19,122 shares ($152.8K)
Inst.
AMERIPRISE FINANCIAL INC — TRIM
11,448 shares ($91.5K)
Price Targets
$6.00
+165.5% upside
Strong Buy
Current $2.26
Low $6.00
Median $6.00
High $6.00
1 analysts
$6.00
$6.00
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 6, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Jan 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.40 ▲ +10.1% | $-0.40 — $-0.40 | 2% YoY | 1 |
| Next Q | $-0.43 ▲ +35.3% | $-0.43 — $-0.43 | 27% YoY | 1 |
| Current FY | $-1.90 ▲ +5.2% | $-1.90 — $-1.90 | -7% YoY | 1 |
| Next FY | $-1.65 ▼ -22.2% | $-1.65 — $-1.65 | 13% YoY | 1 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.6M | — |
| BlackRock, Inc. | $713.3K | — |
| RENAISSANCE TECHNOLOGIES LLC | $307.6K | — |
| TWO SIGMA INVESTMENTS, LP | $269.7K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Ono Richard | A | $3.9K |
| Jun 3, 2026 | Jene Jill | A | $3.9K |
| Jun 3, 2026 | Higuchi John | A | $3.9K |
| Apr 7, 2026 | Higuchi John | BUY | $81.2K |
| Apr 6, 2026 | Higuchi John | BUY | $252.1K |
Reddit Sentiment
23°
Bearish
Bearish
Neutral
Bullish
17 institutional holders with $4.1M total value (516,764 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, BlackRock,. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 50 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 200,668 | $1.6M | 38.8% | — |
| 3 | BlackRock, Inc. | 89,272 | $713.3K | 17.3% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 38,497 | $307.6K | 7.5% | — |
| 5 | TWO SIGMA INVESTMENTS, LP | 33,750 | $269.7K | 6.5% | — |
| 6 | VANGUARD FIDUCIARY TRUST CO | 32,413 | $259.0K | 6.3% | — |
| 7 | CITADEL ADVISORS LLC | 29,088 | $232.4K | 5.6% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 24,908 | $199.0K | 4.8% | — |
| 9 | STATE STREET CORP | 22,407 | $179.0K | 4.3% | — |
| 10 | DIMENSIONAL FUND ADVISORS LP | 19,122 | $152.8K | 3.7% | ADD +57.5% |
| 11 | AMERIPRISE FINANCIAL INC | 11,448 | $91.5K | 2.2% | TRIM -28.9% |
| 12 | BARCLAYS PLC | 9,412 | $75.2K | 1.8% | — |
| 13 | WELLS FARGO & COMPANY/MN | 2,706 | $21.6K | 0.5% | — |
| 14 | Vanguard Global Advisers, LLC | 1,691 | $13.5K | 0.3% | — |
| 15 | FMR LLC | 626 | $5.0K | 0.1% | DOUBLED +713.0% |
| 16 | MORGAN STANLEY | 574 | $4.6K | 0.1% | ADD +30.6% |
| 17 | GROUP ONE TRADING LLC | 132 | $1.1K | 0.0% | TRIM -53.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | ADD | 12,140 | 19,122 | +57.5% | $152.8K | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 16,104 | 11,448 | -28.9% | $91.5K | 2026-Q1 |
| FMR LLC | DOUBLED | 77 | 626 | +713.0% | $5.0K | 2026-Q1 |
| MORGAN STANLEY | ADD | 575 | 751 | +30.6% | $6.0K | 2025-Q4 |
| FMR LLC | ADD | 59 | 77 | +30.5% | $618.00 | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 23,862 | 12,140 | -49.1% | $34.7K | 2025-Q3 |
| UBS Group AG | DOUBLED | 475 | 1,766 | +271.8% | $5.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 2,587 | 49 | -98.1% | $139.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 199 | 475 | +138.7% | $1.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 62 | 2,581 | +4062.9% | $8.2K | 2025-Q1 |
| FMR LLC | DOUBLED | 65 | 237 | +264.6% | $754.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 3 | 199 | +6533.3% | $632.00 | 2025-Q1 |
| GROUP ONE TRADING LLC | TRIM | 423 | 197 | -53.4% | $961.00 | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 59,413 | 3 | -100.0% | $15.00 | 2024-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 11,870 | 18,016 | +51.8% | $80.9K | 2024-Q3 |
| GROUP ONE TRADING LLC | DOUBLED | 16 | 423 | +2543.8% | $1.9K | 2024-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 44 | 56 | +27.3% | $252.00 | 2024-Q3 |
4 unique insiders with 7 transactions. Net insider value: $434.6K ($434.6K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Ono Richard Dana | Director | AWARD | 1,764 | $2.19 | $3.9K |
| Jun 3, 2026 | Jene Jill M. | Director | AWARD | 1,764 | $2.19 | $3.9K |
| Jun 3, 2026 | Higuchi John W. | Director | AWARD | 1,764 | $2.19 | $3.9K |
| Apr 7, 2026 | Higuchi John W. | Director | BUY | 40,000 | $2.03 | $81.2K |
| Apr 6, 2026 | Higuchi John W. | Director | BUY | 123,000 | $2.05 | $252.1K |
| Apr 6, 2026 | Patel Mahesh V. | Chief Executive Officer | BUY | 25,000 | $2.03 | $50.7K |
| Apr 2, 2026 | Patel Mahesh V. | Chief Executive Officer | BUY | 25,000 | $2.02 | $50.5K |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 6 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
3/10
Lipocine filed an 8-K announcing a virtual KOL event on June 12, 2026, to discuss unmet needs in pos
Jun 4, 2026
NEUTRAL
8-K
4/10
Lipocine announced the presentation of Phase 3 clinical data for LPCN 1154 (oral brexanolone) for po
May 26, 2026
NEUTRAL
8-K
4/10
Lipocine announced that its Phase 3 clinical data for LPCN 1154 (oral brexanolone for postpartum dep
May 19, 2026
NEUTRAL
8-K
2/10
Lipocine filed an 8-K announcing management will present at A.G.P.'s Annual Virtual Healthcare Compa
May 18, 2026
BEARISH
8-K
8/10
Lipocine reported Q1 2026 results with a net loss of $3.7M ($0.54 per share), wider than the $1.9M l
May 7, 2026
BEARISH
8-K
6/10
Lipocine Inc. announced the resignation of Dr. Spyros Papapetropoulos as Chairman and Lead Independe
Apr 21, 2026
NEUTRAL
8-K
2/10
Lipocine Inc. updated its corporate presentation for use in investor and analyst meetings. This is a
Apr 2, 2026
BEARISH
8-K
7/10
Lipocine Inc. announced that its Phase 3 trial for LPCN 1154 in postpartum depression (PPD) failed t
Apr 2, 2026
NEUTRAL
8-K
3/10
Lipocine Inc. (LPCN) filed a prospectus supplement to its existing sales agreement with A.G.P./Allia
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.00 mean target
+165.5% upside
Strong Buy (3.00)
$6.00 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $2.26 |
| Target Low | $6.00 |
| Target Mean | $6.00 |
| Target Median | $6.00 |
| Target High | $6.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.40 | $-0.40 | $-0.40 | 2.4% | +10.1% | 1↑ 0↓ | $0.0B | -65.8% | 1 |
| Next Q 2026-09-30 |
$-0.43 | $-0.43 | $-0.43 | 27.1% | +35.3% | — | $0.0B | 91.2% | 1 |
| Current FY 2026-12-31 |
$-1.90 | $-1.90 | $-1.90 | -7.3% | +5.2% | 1↑ 1↓ | $0.0B | -60.7% | 1 |
| Next FY 2027-12-31 |
$-1.65 | $-1.65 | $-1.65 | 13.2% | -22.2% | 0↑ 1↓ | $0.0B | 40.4% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.400 | |
| 7d ago | $-0.440 | +0.040 |
| 30d ago | $-0.445 | +0.045 |
| 60d ago | $-0.610 | +0.210 |
| 90d ago | $-0.610 | +0.210 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 6, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jan 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
23°
Bearish
Bearish
Neutral
Bullish
7 mentions
0 bullish
6 bearish
7 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 14, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 14, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 3, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 3, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
WHAT ARE THE BIGGEST LOSERS PRE-MARKET AND WHY ? >>>>>
▲ 1
💬 1
⚡ 0.5
LPCN MUST SEE LOW FLOATER
▲ 0
💬 1
May 6, 2026
earnings_calendar
LPCN Q1 2026 Earnings Scheduled — 2026-05-06
Apr 2, 2026
short_volume
Short Volume: LPCN — 56.1% short (1.9M / 3.4M)
Short: 1,931,113 | Exempt: 346,277 | TRF Vol: 3,441,023 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Phase Phase 3 — COMPLETED
Apr 1, 2026
clinical_trial_readout
Results Pending: LPCN 1154A (Phase 3) — Completed 75d ago
Trial: A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Sponsor: Lipocine Inc.
Phase: Phase 3 | Completed: 2026-0
Mar 30, 2026
clinical_trial_readout
Results Pending: LPCN 1154A (Phase 3) — Completed 73d ago
Trial: A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Sponsor: Lipocine Inc.
Phase: Phase 3 | Completed: 2026-0
Mar 26, 2026
clinical_trial_readout
Results Pending: LPCN 1154A (Phase 3) — Completed 69d ago
Trial: A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Sponsor: Lipocine Inc.
Phase: Phase 3 | Completed: 2026-0
Mar 11, 2026
earnings_calendar
LPCN Q4 2025 Earnings After Market Close — 2026-03-11